

**HONGBO YANG, PH.D.**  
**Managing Principal**

Phone: 617 425 8175  
Fax: 617 425 8001  
hongbo.yang@analysisgroup.com

111 Huntington Avenue  
14th Floor  
Boston, MA 02199

Dr. Yang is an expert in health economics and outcomes research (HEOR), with extensive experience in developing comprehensive HEOR strategies to support products throughout their entire life cycles. As part of her diverse portfolio of HEOR case work, she has developed robust launch strategies; generated real-world data (RWD); and created clinical, economic, and humanistic evidence to support product value propositions. Notably, Dr. Yang has led case teams in preparing submissions to health technology assessment (HTA) agencies across the world, including those in the UK, France, Germany, Norway, Australia, Canada, and Japan. She has also conducted numerous studies across various therapeutic areas – such as autoimmune diseases, infectious diseases, diabetes, blood disorders, oncology, women’s health, and rare diseases – and worked across diverse treatment paradigms, including one-time interventions involving cell and gene therapies, as well as recurrent treatment regimens. Dr. Yang’s work has been widely published in peer-reviewed journals and featured at health care conferences.

**EDUCATION**

2008            Ph.D., biology, University of Illinois at Urbana-Champaign  
2008            M.S., statistics, University of Illinois at Urbana-Champaign  
2002            B.S., biochemistry, Nankai University, Tianjin, China

**PROFESSIONAL EXPERIENCE**

2009–Present    Analysis Group, Inc.  
                    *Managing Principal (2023–Present)*  
                    *Vice President (2017–2023)*  
                    *Manager (2013–2016)*  
                    *Associate (2011–2012)*  
                    *Senior Analyst (2009–2010)*

**SELECTED PUBLICATIONS (PEER-REVIEWED JOURNALS)**

- DePree B, Shiozawa A, King D, Schild A, Zhou M, **Yang H**, Mancuso S. Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey. *Menopause*. 2023 Sep;30(9):887-897.
- Shiozawa A, Thurston RC, Cook E, **Yang H**, King DD, Kristy RM, Mancuso S. Assessment of women's treatment preferences for vasomotor symptoms due to menopause. *Expert Rev Pharmacoecon Outcomes Res*. 2023 Aug;31:1-12.
- Merkel M, Danese D, Chen C, Wang J, Wu A, **Yang H**, Lin H. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy. *Expert Opin Pharmacother*. 2023 May-Aug;24(10):1205-1214.

- **Yang H**, Bollu V, Lim S, Tesfaye M, Dalal AA, Lax A, Sethi S, Zhao J. Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% Medicare claims database. *Leuk Lymphoma*. 2023 Feb;64(2):339-348.
- Maziarz RT, **Yang H**, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. *Leuk Lymphoma*. 2022 Sep;63(9):2052-2062.
- **Yang H**, Faust E, Gao E, Sethi S, Kitt TM, Kristy RM, Spalding JR, Xu Y. Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test. *J Nucl Cardiol*. 2022 Aug;29(4):1788-1795.
- Lebwohl M, Soliman AM, **Yang H**, Wang J, Freimark J, Puig L. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-Severe psoriasis. *J Dermatolog Treat*. 2022 Jun;33(4):2094-2101.
- Kraus SR, Li J, Kristy RM, Lockfefer A, **Yang H**, Zhou M, Walker DR. Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States. *J Int Med Res*. 2022 May;50(5):3000605221098176.
- Maziarz RT, Zhang J, **Yang H**, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam CS, Salles GA. Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell Lymphoma. *Blood Adv*. 2022 Apr;6(8):2536-2547.
- Schuster SJ, Zhang J, **Yang H**, Agarwal A, Tang W, Martinez-Prieto M, Bollu V, Kuzan D, Maziarz RT, Kersten MJ. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. *Leuk Lymphoma*. 2022 Apr;63(4):845-854.
- Zeidan AM, Qi CZ, **Yang H**, Garnham A, Shah MV, Pandya BJ. Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial. *Leuk Lymphoma*. 2022 Mar;63(3):762-764.
- Lebwohl MG, Soliman AM, **Yang H**, Wang J, Hagan K, Padilla B, Pinter A. Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials. *Dermatol Ther (Heidelb)*. 2022 Feb;12(2):407-418.
- Saeki H, Ishii K, Joshi A, Bensimon AG, **Yang H**, Kawaguchi I. An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. *J Dermatolog Treat*. 2022 Feb;33(1):229-239.
- Setyawan J, Mu F, Zichlin ML, Billmyer E, Downes N, **Yang H**, Azimi N, Strand V, Yarur A. Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease. *Adv Ther*. 2022 Jan;39(1):738-753.

- Setyawan J, Billmyer E, Mu F, Yarur A, Zichlin ML, **Yang H**, Downes N, Azimi N, Strand V. The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases. *Adv Ther.* 2022 Jan;39(1):767-778.
- Verneris MR, Ma Q, Zhang J, Keating A, Tiwari R, Li J, **Yang H**, Agarwal A, Pacaud L. Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. *Blood Adv.* 2021 Dec;5(23):5387-5395.
- Garrison LP, Pezalla E, Towse A, **Yang H**, Faust E, Wu EQ, Li N, Sawyer EK, Recht M. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. *Value Health.* 2021 Nov;24(11):1628-1633.
- Griffin JD, Song Y, **Yang H**, Freimark J, Shah MV. Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes. *Eur J Haematol.* 2021 Nov;107(5):553-565.
- Pandya BJ, Qi CZ, Garnham A, **Yang H**, Shah MV, Zeidan AM. Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia. *J Manag Care Spec Pharm.* 2021 Oct;27(10):1469-1481.
- Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, **Yang H**, Moritz ML. Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study. *Front Med (Lausanne).* 2021 Sep;8:703305.
- Qi CZ, Bollu V, **Yang H**, Dalal A, Zhang S, Zhang J. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. *Clin Ther.* 2021 Aug;43(8):1300-1319.e8.
- Setyawan J, Mu F, Yarur A, Zichlin ML, **Yang H**, Fernan C, Billmyer E, Downes N, Azimi N, Strand V. Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases. *Clin Ther.* 2021 Aug;43(8):1392-1407.e1.
- Li J, Walker DR, Biesbrock G, Kristy RM, **Yang H**, Gao E, Koenigsberg S, Spalding JR, Kitt TM. Factors that impact a patient's experience when undergoing single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in the US: A survey of patients, imaging center staff, and physicians. *J Nucl Cardiol.* 2021 Aug;28(4):1507-1518.
- Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, **Yang H**, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. *Transplant Cell Ther.* 2021 Jun;27(6):506.e1-506.e10.
- Buckner TW, Bocharova I, Hagan K, Bensimon AG, **Yang H**, Wu EQ, Sawyer EK, Li N. Health care resource utilization and cost burden of hemophilia B in the United States. *Blood Adv.* 2021 Apr;5(7):1954-1962.
- Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, **Yang H**, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. *Transplant Cell Ther.* 2021 Mar;27(3):241.e1-241.e11.

- Pandya BJ, **Yang H**, Schmeichel C, Qi CZ, Shah MV. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3mut+ acute myeloid leukemia in a US health plan. *J Med Econ*. 2021 Jan-Dec;24(1):19-28.
- Kilpatrick RD, Chiuve SE, Leslie WD, Wegrzyn LR, Gao W, **Yang H**, Soliman AM, Snabes MC, Koenigsberg S, Zhong J, Xiang C, Watts NB. Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population. *JBMR Plus*. 2020 Nov;4(12):e10401.
- **Yang H**, Hao Y, Qi CZ, Chai X, Wu EQ. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective. *J Manag Care Spec Pharm*. 2020 Aug;26(8):971-980.
- Zhang J, Li J, Ma Q, **Yang H**, Signorovitch J, Wu E. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible? *Adv Ther*. 2020 Jul;37(7):3040-3058.
- Estes SJ, Soliman AM, **Yang H**, Wang J, Freimark J. A Longitudinal Assessment of the Impact of Endometriosis on Patients' Salary Growth and Risk of Leaving the Workforce. *Adv Ther*. 2020 May;37(5):2144-2158.
- Schultz NM, Penson DF, Wilson S, Song Y, **Yang H**, Ramaswamy K, Lowentritt B. Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. *Drug Saf*. 2020 Jan;43(1):23-33. Queiroz Muniz D, Ratto B, **Yang H**, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Lema Medina M, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. *Adv Ther*. 2019 Dec;36(12):3446-3457.
- Liu G, Wu EQ, Ahn J, Kamae I, Xie J, **Yang H**. The Development of Health Technology Assessment in Asia: Current Status and Future Trends. *Value Health Reg Issues*. 2019 Oct;21:39-44.
- Schultz NM, Penson DF, Wilson SD, Song Y, **Yang H**, Ramaswamy K, Lowentritt B. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. *J Manag Care Spec Pharm*. 2019 Aug;25(8):889-897.
- Tzellos T, **Yang H**, Mu F, Calimlim B, Signorovitch J. Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Income. *Br J Dermatol*. 2019 Jul;181(1):147-154.
- Levy BP, Signorovitch JE, **Yang H**, Patterson-Lomba O, Xiang CQ, Parisi M. Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer. *Curr Oncol*. 2019 Jun;26(3):e300-e308.
- Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, **Yang H**. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. *Orphanet J Rare Dis*. 2019 Apr;14(1):89.
- Griffin JD, **Yang H**, Song Y, Kinrich D, Shah MV, Bui CN. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study. *Eur J Haematol*. 2019 Apr;102(4):341-350.

- Kim S, Signorovitch JE, **Yang H**, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. *Adv Ther.* 2018 Oct;35(10):1564-1577.
- Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, **Yang H**, Lechpammer S, Kassabian V. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis. *Adv Ther.* 2018 Oct;35(10):1639-1655.
- Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, **Yang H**, Brown BA, Barlev A, Flanders SC. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. *BMC Urol.* 2018 Sep;18(1):77.
- Jiang R, Law E, Zhou Z, **Yang H**, Wu EQ, Seifeldin R. Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis. *Diabetes Ther.* 2018 Jun;9(3):1021-1036.
- Jiang R, Law E, Zhou Z, **Yang H**, Wu EQ, Seifeldin R. Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis. *Diabetes Ther.* 2018 Jun;9(3):1021-1036.
- Ayyagari R, Neary M, Li S, Rokito A, **Yang H**, Xie J, Benson AB 3rd. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors. *Am Health Drug Benefits.* 2017 Nov;10(8):408-415.
- Surrey ES, Soliman AM, **Yang H**, Du EX, Su B. Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis. *Adv Ther.* 2017 Nov;34(11):2436-2451.
- **Yang H**, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. *J Med Econ.* 2017 Oct;20(10):1056-1065.
- Li J, Houle CR, Spalding JR, **Yang H**, Xiang CQ, Kitt TM, Kristy RM, Wu EQ. Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests. *J Med Econ.* 2017 Aug;20(8):777-785.
- Soliman AM, Du EX, **Yang H**, Wu EQ, Haley JC. Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy. *J Womens Health (Larchmt).* 2017 Jun;26(6):644-654.
- Zhou Z, Chaudhari P, **Yang H**, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R. Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study. *Diabetes Ther.* 2017 Jun;8(3):555-571.
- Wolf D, Skup M, **Yang H**, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. *Clin Ther.* 2017 Apr;39(4):849-862.e6.
- Ostrosky-Zeichner L, Harrington R, Azie N, **Yang H**, Li N, Zhao J, Koo V, Wu EQ. A Risk Score for Fluconazole Failure among Patients with Candidemia. *Antimicrob Agents Chemother.* 2017 Apr;61(5):e02091-16.

- Massoudi M, Balk M, **Yang H**, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. *J Med Econ*. 2017 Feb;20(2):121-128.
- Harrington R, Lee E, **Yang H**, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. *Adv Ther*. 2017 Jan;34(1):207-220.
- Kontoyiannis DP, **Yang H**, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. *BMC Infect Dis*. 2016 Dec;16(1):730.
- Andes D, Azie N, **Yang H**, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J. Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. *Antimicrob Agents Chemother*. 2016 May;60(6):3398-406.
- Soliman AM, **Yang H**, Du EX, Kelley C, Winkel C. The direct and indirect costs associated with endometriosis: a systematic literature review. *Hum Reprod*. 2016 Apr;31(4):712-22.
- Setyawan J, **Yang H**, Cheng D, Cai X, Signorovitch JE, Xie J, Erder MH. Developing a risk score to guide individualized treatment selection in attention/deficit hyperactivity disorder. *Value Health*. 2015 Sep;18(6):824-31.
- Soliman AM, **Yang H**, Du EX, Kelkar SS, Winkel C. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. *Am J Obstet Gynecol*. 2015 Aug;213(2):141-60.
- Bonthapally V, **Yang H**, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post ASCT: median overall survival meta-Analysis. *Curr Med Res Opin*. 2015 Jul;31(7):1377-89.
- Bonthapally V, Wu E, Macalalad A, **Yang H**, Shonukan O, Liu Y, Chi A, Huebner D. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. *Curr Med Res Opin*. 2015 May;31(5):993-1001.
- Macalalad AR, McAuliffe M, **Yang H**, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. *Curr Med Res Opin*. 2015 Mar;31(3):537-45.
- Fuldeore M, **Yang H**, Du EX, Soliman AM, Wu EQ, Winkel C. Healthcare utilization and costs in women diagnosed with endometriosis pre- and post-diagnosis: a longitudinal analysis of claims databases. *Fertil Steril*. 2015 Jan;103(1):163-71.
- Campone M, **Yang H**, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. *J Med Econ*. 2014 Dec;17(12):837-45.
- Lachaine J, De G, Sikirica V, van Stralen J, Hodgkins P, **Yang H**, Heroux J, Ben Amor L. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in Quebec. *Can J Psychiatry*. 2014 Nov;59(11):597-608.

- Wong MK, **Yang H**, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. *Curr Med Res Opin.* 2014 Apr;30(4):537-45.
- **Yang H**, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States. *Appl Health Econ Health Policy.* 2014 Feb;12(1):85-93.
- Sikirica V, Xie J, He TL, Erder M, Hodgkins P, **Yang H**, Samuelson T, and Wu EQ. Immediate-release versus extended-release guanfacine for treatment of attention-deficit/hyperactivity disorder. *Am J Pharm Benefits.* 2013 Jul;5(4):e85-e94.
- Xie J, Diener M, De G, **Yang H**, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. *J Med Econ.* 2013;16(2):278-88.
- Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, **Yang H**, Goldblum O, Okun MM, Mulani PM. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. *Br J Dermatol.* 2012 Dec;167(6):1374-81.
- Bron M, Marynchenko M, **Yang H**, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. *Postgrad Med.* 2012 Jan;124(1):124-132.
- Erder MH, Signorovitch JE, Setyawan J, **Yang H**, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. *J Med Econ.* 2012;15(6):1078-87.
- Kim Le T, Winfree KB, **Yang H**, Marynchenko M, Yu AP, Frois C, Wu EQ. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. *J Med Econ.* 2012;15(4):786-95.
- **Yang H**, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. *J Med Econ.* 2011;14(5):542-552.
- Yu AP, **Yang H**, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. *J Med Econ.* 2011;14(3):315-323.
- Hines KA, Cryderman DE, Flannery KM, **Yang H**, Vitalini MW, Hazelrigg T, Mizzen CA, Wallrath LL. Domains of heterochromatin protein 1 required for *Drosophila melanogaster* heterochromatin spreading. *Genetics.* 2009 Aug;182(4):967-977.
- **Yang H**, Mizzen CA. The multiple facets of histone H4-lysine 20 methylation. Review. *Biochem Cell Biol.* 2009 Feb;87(1):151-161.
- **Yang H**, Pesavento JJ, Starnes TW, Cryderman DE, Wallrath LL, Kelleher NL, Mizzen CA. Preferential dimethylation of histone H4-lysine 20 by Suv4-20. *J Biol Chem.* 2008 May;283(18):12085-92.
- Pesavento JJ, **Yang H**, Kelleher NL, Mizzen CA. Certain and progressive methylation of histone H4 at lysine 20 during the cell cycle. *Mol Cell Biol.* 2008 Jan;28(1):468-486.

- Shi J, Li J, **Yang H**, Wang K, Wu Q, Zhang J. Proliferation and apoptosis of smooth muscle cells in benign prostate hyperplasia. *Chinese J Pathophysiol.* 2005;21(4):817-819.
- **Yang H**, Elcock AH. Association lifetimes of hydrophobic amino acid pairs measured directly from molecular dynamics simulations. *J Am Chem Soc.* 2003 Nov;125(46):13968-13969.